4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,858,938 | -41.0% | 1,717,120 | -16.3% | 0.00% | -50.0% |
| Q2 2023 | $37,051,270 | +5.5% | 2,050,430 | +0.4% | 0.00% | 0.0% |
| Q1 2023 | $35,105,229 | -36.0% | 2,042,189 | -17.3% | 0.00% | 0.0% |
| Q4 2022 | $54,865,718 | +907.8% | 2,470,316 | +264.8% | 0.00% | – |
| Q3 2022 | $5,444,000 | +23.3% | 677,176 | +7.1% | 0.00% | – |
| Q2 2022 | $4,415,000 | -80.4% | 632,525 | -57.5% | 0.00% | -100.0% |
| Q1 2022 | $22,519,000 | -18.5% | 1,489,371 | +18.2% | 0.00% | 0.0% |
| Q4 2021 | $27,637,000 | +220.6% | 1,259,660 | +294.1% | 0.00% | – |
| Q3 2021 | $8,621,000 | +116.3% | 319,662 | +93.2% | 0.00% | – |
| Q2 2021 | $3,985,000 | -14.0% | 165,492 | +54.9% | 0.00% | – |
| Q1 2021 | $4,634,000 | – | 106,833 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |